Category: Inside The Vault

All Podcast Categories
S4-E49-6-NITs-TLM-2022

S4-49.6 – Conversations from the Vault: NITs at TLM 2022

This Vault conversation stems from the wrap-up to TLM2022. In the episode, the panel (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Ken Cusi, Wayne Eskridge and Roger Green) addresses several topics from the program. This one focuses largely on NITs.

S4-41.6 - From the Vault: Highlights from Paris NASH 2021

S4-41.6 – From the Vault: Highlights from Paris NASH 2021

In this episode From the Vault, Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from the 2021 Paris NASH meeting, an event with exciting scientific messages and insights. This episode has played out to be by far the most downloaded segment in the podcast’s history!

S4-34.6 - From the Vault: Presentation on Efruxifermin in NASH with Fibrosis

S4-34.6 – From the Vault: Presentation on Efruxifermin in NASH with Fibrosis

On the final morning of the 2022 AASLD Liver Meeting, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discussed their key takeaways and impressions. Stephen leads this conversation From the Vault to highlight his presentation of results from Akero Therapeutics’ Phase 2b HARMONY Study.

S4-33.5 - From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

S4-33.5 – From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

Last year, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not). This conversation From the Vault revisits still relevant takeaways as the podcast continues its coverage of emerging stories from EASL Congress 2023.

S4-24.4 - INCBCN Day 2 Summary

S4-24.4 – INCBCN Day 2 Summary

Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation looks into the second day of the conference and the impact that the FDA ADCOM on obeticholic acid has on all of these issues discussed.

S4-21.5 - From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

S4-21.5 – From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

Roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not).

S4-20.6 - From the Vault: Discussing NITs and Final Thoughts on NAFLD Summit

S4-20.6 – From the Vault: Discussing NITs and Final Thoughts on NAFLD Summit

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation From the Vault, the group discusses NITs and what will change between now and when this conference convenes next year.

S4-19.6 - From the Vault: REGENERATE Redux: Clearing The Finish Line?

S4-19.6 – From the Vault: REGENERATE Redux: Clearing The Finish Line?

Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation asks (and attempts to answer) whether the REGENERATE reanalysis is likely to succeed in getting the drug approved.

S4-18.6 - From the Vault: Clinical Care Pathway: What Can Be Done Today?

S4-18.6 – From the Vault: Clinical Care Pathway: What Can Be Done Today?

Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation From the Vault answers the question “What Can Be Done Today?” in terms of screening and patient management without approved drugs.